[ad_1]
According to Cristina Cassetti, the Italian virologist who works in the US, being deputy director of the division of “Microbiology and Infectious Diseases” of the Institute of Infectious Diseases directed by Anthony Fauci, it is very possible that by December two vaccines will already be authorized in the States United. against Covid-19:
“The data provided by Pfizer on the 90% effectiveness of their vaccine is excellent,” Dr. Cassetti told ANSA, “but we must analyze the details.” In the coming days we are also waiting for the dates of the third Modern phase and we hope that in this case we will also receive excellent news ”.
The impact of the anti-Covid vaccine will already be significant during the summer, and next winter it will be possible to return to normal life. Professor Ugur Sahin, one of the creators of the vaccine, co-founder of BioNTech, which is developing the drug with Pfizer, is convinced of this. According to Sahin, the BBC reports, this winter will remain difficult, because the vaccine will not yet have a large impact on the number of people infected.
The vaccine that saves lives
Pfizer announced earlier this week that its Covid-19 vaccine is more than 90% effective, but experts warn that there are still many unknowns.
The director general of the World Health Organization (WHO) said Tuesday that the experimental vaccine developed by the US group Pfizer is “very promising”, at a time when other treatments proposed by several manufacturers in the pharmaceutical industry are expected. . .
But the Pfizer vaccine, based on a new technology that uses synthetic messenger RNA to activate the immune system against the new coronavirus, brings with it a number of special challenges, as it must be stored at temperatures of at least 70 degrees Celsius. values equivalent to those recorded in winters in Antarctica.
The need to store this vaccine at extremely low temperatures could complicate vaccination programs, especially in regions of Asia and Africa where the climate is hot, distances are great and the necessary infrastructure is poor or even non-existent.
The US group Pfizer announced on Monday that its anti-COVID-19 vaccine is more than 90% effective and published preliminary data from its phase 3 clinical study. Data on the safety of the vaccine, developed in collaboration with the German company BioNTech , to be released later this month.
